HEM Pharma KOSDAQ:A376270 Stock Report

Last Price

₩18.04k

Market Cap

₩125.6b

7D

10.9%

1Y

n/a

Updated

05 Jan, 2025

Data

Company Financials +

HEM Pharma Inc.

KOSDAQ:A376270 Stock Report

Market Cap: ₩125.6b

A376270 Stock Overview

Operates as a microbiome healthcare company in South Korea and internationally. More details

A376270 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Has not reported any financial data

Does not have a meaningful market cap (₩126B)

Volatile share price over the past 3 months compared to the KR market

My Notes

Capture your thoughts, links and company narrative

HEM Pharma Inc. Competitors

BIO-FD&CLtd

KOSDAQ:A251120

₩121.7b

Helixmith

KOSDAQ:A084990

₩130.3b

DNA Link

KOSDAQ:A127120

₩132.2b

Shaperon

KOSDAQ:A378800

₩118.5b

Price History & Performance

Summary of share price highs, lows and changes for HEM Pharma
Historical stock prices
Current Share Price	₩18,040.00
52 Week High	₩20,650.00
52 Week Low	₩11,520.00
Beta	0
1 Month Change	45.02%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	10.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	A376270	KR Biotechs	KR Market
7D	10.9%	3.3%	2.2%
1Y	n/a	9.8%	-8.3%

Return vs Industry: Insufficient data to determine how A376270 performed against the KR Biotechs industry.

Return vs Market: Insufficient data to determine how A376270 performed against the KR Market.

Price Volatility

Is A376270's price volatile compared to industry and market?
A376270 volatility
A376270 Average Weekly Movement	11.9%
Biotechs Industry Average Movement	8.8%
Market Average Movement	6.6%
10% most volatile stocks in KR Market	12.8%
10% least volatile stocks in KR Market	3.4%

Stable Share Price: A376270's share price has been volatile over the past 3 months compared to the KR market.

Volatility Over Time: Insufficient data to determine A376270's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2016	n/a	Yosep Ji	www.hempharma.bio

HEM Pharma Inc. operates as a microbiome healthcare company in South Korea and internationally. The company offers health functional food products, such as Nutrilite and my LAB microbiome solution. It also engages in the personalized analysis service and CDMO businesses.

HEM Pharma Inc. Fundamentals Summary

How do HEM Pharma's earnings and revenue compare to its market cap?
A376270 fundamental statistics
Market cap	₩125.60b
Earnings (TTM)	₩0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is A376270 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A376270 income statement (TTM)
Revenue	₩0
Cost of Revenue	₩0
Gross Profit	₩0
Other Expenses	₩0
Earnings	₩0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did A376270 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/05 09:13
End of Day Share Price	2025/01/03 00:00
Earnings	N/A
Annual Earnings	N/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

HEM Pharma Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jongsun Park	Eugene Investment & Securities Co Ltd.